Colorectal Cancer
Cetuximab and/or Bevacizumab + Combination Chemotherapy For Metastatic Colorectal Cancer (CTSU C80405)
A Phase III Trial of Irinotecan(Camptosar)/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab (Avastin), or Cetuximab (C225) (Erbitux), or With The Combination of Bevacizumab, or Cetuximab For Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Investigator: Fred Appelbaum, MD; Conditions: Colon Cancer, Rectal Cancer, Colorectal Cancer; Status: Recruiting; Study ID: NCT00265850
Randomised Comparative Study Of Folfox6m Plus SIR-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma
Investigator: Samuel Whiting, MD, PhD; Conditions: Colorectal Cancer, Colorectal Carcinoma, Liver Metastases; Status: Recruiting; Study ID: NCT00724503
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab (Avastin), Oxaliplatin, and a Fluoropyrimidine
Investigator: Veena Shankaran; Conditions: Colon Cancer; Gastrointestinal Cancer; Rectal Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01183780
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Not Recruiting; Study ID: NCT01063816
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer, Colorectal Adenocarcinoma; Status: Recruiting; Study ID: NCT00729664
Join Us On